We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Read MoreHide Full Article
Key Takeaways
{\"0\":\"HALO posted Q2 EPS of $1.54, which beat estimates by $0.31 and rose 69.2% year over year.\",\"1\":\"Q2 revenues grew 41% to $325.7M, driven by strong royalties from Darzalex SC, Phesgo, and Vyvgart Hytrulo.\",\"2\":\"HALO raised its 2025 guidance for revenues, royalties, EBITDA and EPS on continued royalty strength.\"}
Halozyme Therapeutics (HALO - Free Report) reported second-quarter 2025 adjusted earnings of $1.54 per share, which comprehensively beat the Zacks Consensus Estimate of $1.23. Earnings rose 69.2% year over year.
Total revenues in the second quarter increased 41% year over year to $325.7 million. Revenues too surpassed the Zacks Consensus Estimate of $286 million.
The top-line growth was primarily driven by higher royalty payments from Roche (RHHBY - Free Report) for Phesgo and J&J (JNJ - Free Report) for subcutaneous Darzalex (daratumumab), as well as argenx’s Vyvgart Hytrulo during the second quarter.
Several companies use HALO’s Enhanze technology to develop a subcutaneous formulation of their currently marketed drugs. Halozyme now has several marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s Darzalex and Roche’s Phesgo.
Shares of Halozyme were up 5.3% in after-hours trading on Aug. 5, owing to the better-than-expected results as well as an increased financial outlook for 2025.
Year to date, shares of Halozyme have rallied 27.2% compared with the industry’s rise of 1.9%.
Image Source: Zacks Investment Research
HALO's Q2 Results in Detail
Halozyme’s top line comprises product sales, royalties and revenues under collaborative agreements.
Royalty revenues totaled $205.6 million in the second quarter, up 65% from the year-ago quarter’s level. This was mainly due to the robust demand for Phesgo, subcutaneous Darzalex and Vyvgart Hytrulo, on which it earns royalties.
Royalty revenues beat our model estimate of $168.7 million.
Product sales were $81.5 million in the second quarter, up 3.3% from the year-ago quarter’s level. HALO has two commercial proprietary products, Hylenex and Xyosted, with the latter acquired from Antares Pharma in 2022.
Product sales missed our model estimate of $87.7 million.
Revenues under collaborative agreements were $38.6 million in the second quarter, increasing 40.4% on a year-over-year basis.
Adjusted EBITDA was $225.5 million in the second quarter, reflecting a 64.6% increase from the prior-year quarter.
Halozyme had cash, cash equivalents and marketable securities of $548.2 million as of June 30, 2025, compared with $747.9 million as of March 31, 2025.
HALO's 2025 Guidance Raised
Owing to increased royalty revenues due to the continued strong growth of JNJ’s Darzalex SC and RHHBY’s Phesgo and the robust growth of Vyvgart Hytrulo, the company raised its total revenue guidance for 2025.
Total revenues are now expected in the range of $1.28 billion to $1.36 billion compared with the earlier projection of $1.20 billion to $1.28 billion.
Royalty revenues are now anticipated in the range of $825-$860 million, compared with the previous expectation of $750-$785 million.
Adjusted EBITDA is now expected in the band of $865-$915 million, compared with the earlier expectation of $790-$840 million.
Adjusted earnings are now expected in the range of $6.00-$6.40 per share in 2025 versus the previous projection of $5.30-$5.70 per share.
Halozyme’s earnings per share guidance does not consider the impact of potential future share repurchases.
Halozyme Therapeutics, Inc. Price, Consensus and EPS Surprise
In the past 60 days, estimates for Immunocore’s 2025 loss per share have narrowed from 86 cents to 68 cents. Loss per share estimates for 2026 have narrowed from $1.34 to $1.10 during the same period. IMCR stock has increased 10.2% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 76.18%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
Key Takeaways
Halozyme Therapeutics (HALO - Free Report) reported second-quarter 2025 adjusted earnings of $1.54 per share, which comprehensively beat the Zacks Consensus Estimate of $1.23. Earnings rose 69.2% year over year.
Total revenues in the second quarter increased 41% year over year to $325.7 million. Revenues too surpassed the Zacks Consensus Estimate of $286 million.
The top-line growth was primarily driven by higher royalty payments from Roche (RHHBY - Free Report) for Phesgo and J&J (JNJ - Free Report) for subcutaneous Darzalex (daratumumab), as well as argenx’s Vyvgart Hytrulo during the second quarter.
Several companies use HALO’s Enhanze technology to develop a subcutaneous formulation of their currently marketed drugs. Halozyme now has several marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s Darzalex and Roche’s Phesgo.
Shares of Halozyme were up 5.3% in after-hours trading on Aug. 5, owing to the better-than-expected results as well as an increased financial outlook for 2025.
Year to date, shares of Halozyme have rallied 27.2% compared with the industry’s rise of 1.9%.
Image Source: Zacks Investment Research
HALO's Q2 Results in Detail
Halozyme’s top line comprises product sales, royalties and revenues under collaborative agreements.
Royalty revenues totaled $205.6 million in the second quarter, up 65% from the year-ago quarter’s level. This was mainly due to the robust demand for Phesgo, subcutaneous Darzalex and Vyvgart Hytrulo, on which it earns royalties.
Royalty revenues beat our model estimate of $168.7 million.
Product sales were $81.5 million in the second quarter, up 3.3% from the year-ago quarter’s level. HALO has two commercial proprietary products, Hylenex and Xyosted, with the latter acquired from Antares Pharma in 2022.
Product sales missed our model estimate of $87.7 million.
Revenues under collaborative agreements were $38.6 million in the second quarter, increasing 40.4% on a year-over-year basis.
Adjusted EBITDA was $225.5 million in the second quarter, reflecting a 64.6% increase from the prior-year quarter.
Halozyme had cash, cash equivalents and marketable securities of $548.2 million as of June 30, 2025, compared with $747.9 million as of March 31, 2025.
HALO's 2025 Guidance Raised
Owing to increased royalty revenues due to the continued strong growth of JNJ’s Darzalex SC and RHHBY’s Phesgo and the robust growth of Vyvgart Hytrulo, the company raised its total revenue guidance for 2025.
Total revenues are now expected in the range of $1.28 billion to $1.36 billion compared with the earlier projection of $1.20 billion to $1.28 billion.
Royalty revenues are now anticipated in the range of $825-$860 million, compared with the previous expectation of $750-$785 million.
Adjusted EBITDA is now expected in the band of $865-$915 million, compared with the earlier expectation of $790-$840 million.
Adjusted earnings are now expected in the range of $6.00-$6.40 per share in 2025 versus the previous projection of $5.30-$5.70 per share.
Halozyme’s earnings per share guidance does not consider the impact of potential future share repurchases.
Halozyme Therapeutics, Inc. Price, Consensus and EPS Surprise
Halozyme Therapeutics, Inc. price-consensus-eps-surprise-chart | Halozyme Therapeutics, Inc. Quote
HALO's Zacks Rank & Stock to Consider
Halozyme currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is Immunocore (IMCR - Free Report) , sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Immunocore’s 2025 loss per share have narrowed from 86 cents to 68 cents. Loss per share estimates for 2026 have narrowed from $1.34 to $1.10 during the same period. IMCR stock has increased 10.2% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 76.18%.